Intravenous Infusions is trading at GHS 0.55 (-3.51%) amid continued selling pressure following consecutive declines through September 9, 2026.
- No company-specific announcement, earnings release, filing, transaction, or analyst action has been identified for September 11, 2026.
- Broader U.S. markets are rising, so the decline does not clearly track today’s global risk sentiment.
- External coverage confirms recent weakness but provides no catalyst; the reason remains unconfirmed.